Analytics Link Ecosystem
IQVIA Analytics Link Ecosystem establishes deep connections across our key data assets.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSArticle
Navigating the Shifting Landscape of Myasthenia Gravis Treatment: The Impact of Expensive Targeted Therapies
Jan 16, 2024
Myasthenia Gravis (MG) is a rare and chronic autoimmune disorder characterized by muscle weakness and fatigue. This condition occurs when the immune system attacks acetylcholine receptors (AChR) in the neuromuscular junctions, disrupting nerve-muscle communication and causing muscle weakness which can impact various parts of the body, including the eyes, face, throat, and limbs. In some cases, antibodies may also attack other proteins such as the muscle-specific kinase (MuSK) or low density lipoprotein receptor-related protein 4 (LRP4), worsening the condition. MG can affect people of all ages and genders, but it is more common in women under 40 years old and men over 60.
Over the years, the approach to treating MG has evolved significantly. Standard treatments traditionally included acetylcholinesterase (AChE) inhibitors, corticosteroids, and other immunosuppressive drugs, which broadly modify the immune system. AChE inhibitors work by blocking the enzyme AChE which breaks down acetylcholine, a neurotransmitter vital for muscle contraction. By inhibiting this enzyme, more acetylcholine remains available at the neuromuscular junction improving muscle strength. It is the most prescribed first line treatment for MG, which according to IQVIA's Forecast Link is projected to have high volume but flat sales during the forecast period. Corticosteroids can help by decreasing the production of antibodies that interfere with the transmission of nerve signals to muscles. Other immunosuppressive drugs with fewer side effects are used when patients do not respond sufficiently to AChE and corticosteroids or are contraindicated to corticosteroids.
The current market leader acts by inhibiting the complement system but is losing its US patent in 2027. It is expected to lose its position to a drug which acts by inhibiting the neonatal Fc receptor (FcRn) and offers better efficacy without any boxed warning. Before 2017, there was a significant unmet need for targeted therapies as only symptomatic treatments were available for patients suffering from MG. The landscape of MG treatment is set to change significantly, with new drugs targeting intricate nuances of the body's immune response.
To read more, fill in your details on the left to download the article.
Over the years, the approach to treating MG has evolved significantly. Standard treatments traditionally included acetylcholinesterase (AChE) inhibitors, corticosteroids, and other immunosuppressive drugs, which broadly modify the immune system. AChE inhibitors work by blocking the enzyme AChE which breaks down acetylcholine, a neurotransmitter vital for muscle contraction. By inhibiting this enzyme, more acetylcholine remains available at the neuromuscular junction improving muscle strength. It is the most prescribed first line treatment for MG, which according to IQVIA's Forecast Link is projected to have high volume but flat sales during the forecast period. Corticosteroids can help by decreasing the production of antibodies that interfere with the transmission of nerve signals to muscles. Other immunosuppressive drugs with fewer side effects are used when patients do not respond sufficiently to AChE and corticosteroids or are contraindicated to corticosteroids.
The current market leader acts by inhibiting the complement system but is losing its US patent in 2027. It is expected to lose its position to a drug which acts by inhibiting the neonatal Fc receptor (FcRn) and offers better efficacy without any boxed warning. Before 2017, there was a significant unmet need for targeted therapies as only symptomatic treatments were available for patients suffering from MG. The landscape of MG treatment is set to change significantly, with new drugs targeting intricate nuances of the body's immune response.
To read more, fill in your details on the left to download the article.